Investment Analysts’ Recent Ratings Updates for uniQure (QURE)

uniQure (NASDAQ: QURE) has recently received a number of price target changes and ratings updates:

• 12/11/2025 – uniQure had its price target lowered by analysts at Stifel Nicolaus from $50.00 to $40.00. They now have a “buy” rating on the stock.
• 12/8/2025 – uniQure had its price target lowered by analysts at Mizuho from $60.00 to $33.00. They now have an “outperform” rating on the stock.
• 12/8/2025 – uniQure was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/4/2025 – uniQure had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $53.00 price target on the stock.
• 11/30/2025 – uniQure was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/22/2025 – uniQure was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/12/2025 – uniQure had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $60.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – uniQure had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/11/2025 – uniQure had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $53.00 price target on the stock.
• 11/10/2025 – uniQure had its price target lowered by analysts at Leerink Partners from $68.00 to $60.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – uniQure had its “buy” rating reaffirmed by analysts at Benchmark Co..
• 11/4/2025 – uniQure had its price target lowered by analysts at HC Wainwright from $110.00 to $70.00. They now have a “buy” rating on the stock.
• 11/4/2025 – uniQure had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $56.00 to $38.00. They now have a “neutral” rating on the stock.
• 11/4/2025 – uniQure was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
• 11/3/2025 – uniQure had its price target lowered by analysts at Royal Bank Of Canada from $65.00 to $45.00. They now have an “outperform” rating on the stock.
• 11/3/2025 – uniQure had its price target lowered by analysts at Chardan Capital from $76.00 to $53.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, Director Robert Gut sold 31,434 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the transaction, the director directly owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. This trade represents a 43.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 314,560 shares of company stock worth $12,362,568 over the last ninety days. Company insiders own 4.79% of the company’s stock.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.